Close Menu
PNN DigitalPNN Digital
    Facebook X (Twitter) Instagram
    PNN DigitalPNN Digital
    • Business
    • National
    • Entertainment
    • Lifestyle
    • Education
    • Press Release
    • Submit Your PR
    PNN DigitalPNN Digital
    Home - Business - Amrit Noni Ortho Plus Clinical Trial Completed Successfully, Announces Dr. A.K. Srinivasamurthy
    Business

    Amrit Noni Ortho Plus Clinical Trial Completed Successfully, Announces Dr. A.K. Srinivasamurthy

    NaquiyahBy NaquiyahJanuary 11, 2025No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Amrit
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Bengaluru (Karnataka) [India], January 11:  In a significant milestone for Ayurvedic medicine, Amrit Noni has successfully completed human clinical trials for its flagship product, Amrit Noni Ortho Plus. Conducted in collaboration with Nalanda Clinserve under the stringent guidelines of CTRI-Reg India, the trial underscores the brand’s commitment to providing high-quality, effective solutions to its customers.

    Addressing a press conference in Bengaluru, Dr. A.K. Srinivasamurthy, Managing Director of ValYou Products Ltd., emphasized the pressing need for innovative treatments for arthritis, a condition affecting over 210 million people in India—15% of the population. Arthritis, which includes more than 100 types, such as osteoarthritis, rheumatoid arthritis, and gout, is more prevalent than cancer, AIDS, and diabetes. He noted, “Stress and unhealthy lifestyle changes have made arthritis a problem for the younger population as well. While there is no complete cure, we must focus on safer and more effective management strategies.”

    For the past 15 years, Amrit Noni has been a trusted name in Ayurvedic medicine. The latest clinical trial, a double-blind and randomized study, validated the efficacy of Amrit Noni Ortho Plus in managing conditions like osteoarthritis, rheumatoid arthritis, and gout.

    Unique Formulation with Proven Results

    Smt. Mangalambike, Managing Director of Om Shree Marketing Solutions Pvt. Ltd. , highlighted the advanced research and development behind the product. She stated, “Amrit Noni Ortho Plus, developed in collaboration with experienced Ayurvedic doctors and scientists, has emerged as India’s best-selling product for joint pain management. Over 30 lakh satisfied customers have found relief from knee pain, back pain, and hip pain with its unique and effective formula.”

    The brand’s dedication to rigorous scientific research has previously yielded success. Earlier, it conducted a clinical trial for Amrit Noni D Plus and completed cell line studies on cancer cells with its product Canci-Care.

    Clinical Trial Highlights

    Dr. B.G. Varuni, Head of Clinical Research at Nalanda Clinserve, elaborated on the Varanasi-based human clinical trial . The study, involving 40 patients for each condition—osteoarthritis, rheumatoid arthritis, and gout—was conducted over six months. Patients were divided into active and placebo groups and assessed at two-month intervals.

    Key findings include:

    •  Osteoarthritis: Significant improvements in pain, mobility, blood calcium, magnesium levels, and bone mineral density compared to the placebo group.
    • Rheumatoid Arthritis: Marked reduction in C-reactive protein (CRP), rheumatoid factor (RA factor), and ESR, with improvements in serum immunoglobulin levels and antinuclear antibody (ANA) levels.
    • Gout: Patients experienced reduced pain and inflammation, improved quality of life, and well-functioning kidneys and liver without side effects.

    Speaking at the press conference, Ayurvedic experts Dr. Sandeep Benakal and Dr. Mahantaswamy Hiremath commended the breakthrough research.

    Amrit Noni continues to set benchmarks in Ayurvedic healthcare by combining traditional wisdom with modern scientific validation.

    For further information, please contact:

    +91 99453 50505 / +91 98452 03918

    If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

    Amrit Noni Dr A. K. Srinivasamurthy Ortho Plus Clinical Trial Trial Completed Successfully
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Naquiyah

      Related Posts

      “Too Pretty to Eat, Too Magical to Miss” —This Cotton Candy Art that’s Taking Instagram by Storm

      June 16, 2025

      Sundeep Bhutoria Nominated to the Board of Victoria Memorial Hall by Ministry of Culture

      June 14, 2025

      Teen Prodigy Tegh Munjral Kalra Debuts with Gripping Novel -The Trials of the Wasteland

      June 14, 2025
      Add A Comment

      Comments are closed.

      Recent Posts
      • “Too Pretty to Eat, Too Magical to Miss” —This Cotton Candy Art that’s Taking Instagram by Storm
      • Sundeep Bhutoria Nominated to the Board of Victoria Memorial Hall by Ministry of Culture
      • Teen Prodigy Tegh Munjral Kalra Debuts with Gripping Novel -The Trials of the Wasteland
      • OneWall Communities Champions Resident-Centered Living with Tech-Enabled Property Management
      • CMOs’ Charcha Kolkata 2025 Concludes on High Note, Celebrates Visionary Marketing Leadership with MAA Awards

      “Too Pretty to Eat, Too Magical to Miss” —This Cotton Candy Art that’s Taking Instagram by Storm

      June 16, 2025

      Sundeep Bhutoria Nominated to the Board of Victoria Memorial Hall by Ministry of Culture

      June 14, 2025

      Teen Prodigy Tegh Munjral Kalra Debuts with Gripping Novel -The Trials of the Wasteland

      June 14, 2025

      OneWall Communities Champions Resident-Centered Living with Tech-Enabled Property Management

      June 14, 2025

      CMOs’ Charcha Kolkata 2025 Concludes on High Note, Celebrates Visionary Marketing Leadership with MAA Awards

      June 14, 2025

      Vedanta Lanjigarh Launches Mega Drive: 1 Lakh+ Trees Across Kalahandi and Rayagada

      June 14, 2025
      PNN Digital
      2025 © pnn.digital

      Type above and press Enter to search. Press Esc to cancel.